This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Discussing AstraZeneca and Daiichi Sankyo’s DESTINY trial data presented at ASCO 2023 on Enhertu in patients with HER2 advanced solid tumors

Ticker(s): AZN, DSKYF

Who's the expert?

Institution: Hummingbird Biotherapeutics

  • Chief Medical Officer (part-time) of Hummingbird Biotherapeutics (formerly CMO at ImClone and Stemline Therapeutics).
  • Focused on the comprehensive development and registration strategies of cancer therapeutics of all types; integrally involved with the development and registration of more than 12 cancer therapeutics.
  • While at Johns Hopkins University School of Medicine, he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents; has published approximately 315 manuscripts in both the nonclinical and clinical research fields.

Interview Goal
On this call we will be discussing the potential of AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) in patients with HER2-expressing advanced solid tumors based on results from the DESTINY-PanTumor02 Phase II trial and the DESTINY-CRC02 Phase II trial that was recently presented at ASCO 2023.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.